Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer

Vanesa Gregorc, Vienna Ludovini, Lorenza Pistola, Samir Darwish, Irene Floriani, Guido Bellezza, Angelo Sidoni, Antonio Cavaliere, Massimo Scheibel, Verena De Angelis, Emilio Bucciarelli, Maurizio Tonato

Research output: Contribution to journalArticle

Abstract

Purpose: Tumors with p53 overexpression have been associated with enhanced resistance to cisplatin-based chemotherapy in a few and small studies involving non-small cell lung cancer. The relationships and interactions between p53, Rb and bcl-2 immunostaining, clinical parameters and response to cisplatin-based chemotherapy were evaluated in the present study. Experimental design: Histological specimens obtained by bronchial or fine-needle biopsy from patients who underwent cisplatin-based chemotherapy between 1992 and 1999 were evaluated by immunostaining. Results: There were 102 patients, 88 men. Median age was 63 years; 47 had stage III and 55 stage IV disease. Forty-six tumor samples (45%) had positive immunostaining for p53, 61 (59%) had negative immunostaining for Rb and 8 (8%) had positive immunostaining for bcl-2. The response rate of the group with p53 positive immunostaining was 26% versus 57% of the p53 negative group (P=0.004). In multivariate analyses p53 positive immunostaining was identified as an independent predictive factor for resistance to cisplatin-based chemotherapy (P=0.006). Conclusions: Our study confirmed an association of p53 immunostaining and response rate of patients treated with cisplatin-based chemotherapy.

Original languageEnglish
Pages (from-to)41-48
Number of pages8
JournalLung Cancer
Volume39
Issue number1
DOIs
Publication statusPublished - Jan 1 2003

Keywords

  • bcl-2
  • Chemotherapy
  • Cisplatin
  • Lung cancer
  • p53
  • Resistance
  • Retinoblastoma

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Gregorc, V., Ludovini, V., Pistola, L., Darwish, S., Floriani, I., Bellezza, G., Sidoni, A., Cavaliere, A., Scheibel, M., De Angelis, V., Bucciarelli, E., & Tonato, M. (2003). Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer, 39(1), 41-48. https://doi.org/10.1016/S0169-5002(02)00391-4